Article Versions Notes

Alvarado-Miranda A, Lara-Medina FU, Muñoz-Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, Sanchez Benitez D, Limón Rodríguez JA, Arce Salinas CH, Guijosa A, et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Current Oncology. 2023; 30(7):6097-6110. https://doi.org/10.3390/curroncol30070454

Alvarado-Miranda, Alberto, Fernando Ulises Lara-Medina, Wendy R. Muñoz-Montaño, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesús Alberto Limón Rodríguez, Claudia Haydee Arce Salinas, Alberto Guijosa, and et al. 2023. "Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer" Current Oncology 30, no. 7: 6097-6110. https://doi.org/10.3390/curroncol30070454

Alvarado-Miranda, A., Lara-Medina, F. U., Muñoz-Montaño, W. R., Zinser-Sierra, J. W., Galeana, P. A. C., Garza, C. V., Sanchez Benitez, D., Limón Rodríguez, J. A., Arce Salinas, C. H., Guijosa, A., & Arrieta, O. (2023). Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Current Oncology, 30(7), 6097-6110. https://doi.org/10.3390/curroncol30070454